↓ Skip to main content

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial

Overview of attention for article published in Trials, June 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)

Mentioned by

twitter
28 tweeters
patent
1 patent
facebook
1 Facebook page

Citations

dimensions_citation
110 Dimensions

Readers on

mendeley
138 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
Published in
Trials, June 2009
DOI 10.1186/1745-6215-10-39
Pubmed ID
Authors

Matthew R Sydes, Mahesh KB Parmar, Nicholas D James, Noel W Clarke, David P Dearnaley, Malcolm D Mason, Rachel C Morgan, Karen Sanders, Patrick Royston

Abstract

The multi-arm multi-stage (MAMS) trial is a new paradigm for conducting randomised controlled trials that allows the simultaneous assessment of a number of research treatments against a single control arm. MAMS trials provide earlier answers and are potentially more cost-effective than a series of traditionally designed trials. Prostate cancer is the most common tumour in men and there is a need to improve outcomes for men with hormone-sensitive, advanced disease as quickly as possible. The MAMS design will potentially facilitate evaluation and testing of new therapies in this and other diseases.

Twitter Demographics

The data shown below were collected from the profiles of 28 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 138 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 1%
China 1 <1%
Vietnam 1 <1%
Unknown 134 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 34 25%
Student > Master 18 13%
Student > Ph. D. Student 17 12%
Other 11 8%
Professor 10 7%
Other 27 20%
Unknown 21 15%
Readers by discipline Count As %
Medicine and Dentistry 60 43%
Mathematics 9 7%
Psychology 5 4%
Agricultural and Biological Sciences 5 4%
Biochemistry, Genetics and Molecular Biology 4 3%
Other 23 17%
Unknown 32 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 July 2020.
All research outputs
#1,447,241
of 21,767,865 outputs
Outputs from Trials
#409
of 5,559 outputs
Outputs of similar age
#22,090
of 323,803 outputs
Outputs of similar age from Trials
#1
of 1 outputs
Altmetric has tracked 21,767,865 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,559 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.9. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,803 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them